miRagen Therapeutics is a biopharmaceutical company discovering and developing innovative microRNA (miRNA)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. The Company leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners.
TypePublic
HQBoulder, US
Founded2007
Size (employees)51 (est)
Websitemiragen.com
miRagen Therapeutics was founded in 2007 and is headquartered in Boulder, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at miRagen Therapeutics

William S. Marshall

William S. Marshall

Board of Directors Member, CO-Founder, President and Chief Executive Officer, Miragen Therapeutics
Paul Rubin

Paul Rubin

Executive Vice President of Research and Development
Show more

miRagen Therapeutics Office Locations

miRagen Therapeutics has an office in Boulder
Boulder, US (HQ)
6200 Lookout Rd.
Show all (1)
Report incorrect company information

miRagen Therapeutics Financials and Metrics

miRagen Therapeutics Revenue

miRagen Therapeutics's revenue was reported to be $4 m in FY, 2017
USD

Revenue (Q3, 2018)

944.0k

Net income (Q3, 2018)

(9.0m)

EBIT (Q3, 2018)

(9.2m)

Market capitalization (14-Dec-2018)

91.3m

Closing stock price (14-Dec-2018)

3.0

Cash (30-Sep-2018)

31.7m

EV

60.9m
miRagen Therapeutics's current market capitalization is $91.3 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

2.5m3.3m4.0m

Cost of goods sold

2.5m2.5m

Gross profit

66.0k789.0k

Gross profit Margin, %

3%24%
Quarterly
USDQ2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

1.3m734.0k501.0k818.0k874.0k889.0k462.0k718.0k1.6m4.8m2.2m944.0k

Cost of goods sold

675.7k678.0k577.0k629.0k628.0k599.0k

Gross profit

597.8k56.0k(76.0k)189.0k246.0k290.0k

Gross profit Margin, %

47%8%(15%)23%28%33%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

10.8m3.3m47.4m

Accounts Receivable

394.0k524.0k1.5m

Inventories

187.0k64.0k

Current Assets

11.7m4.3m51.9m
Quarterly
USDQ2, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

7.7m10.4m12.1m8.6m6.5m5.4m54.3m46.3m42.8m78.1m43.4m31.7m

Accounts Receivable

1.4m581.0k547.0k490.0k658.0k733.0k277.0k539.0k635.0k4.8m1.2m1.4m

Inventories

193.1k536.0k364.0k269.0k213.0k62.0k

Current Assets

9.8m11.9m13.6m9.7m8.0m6.5m56.9m49.4m46.4m86.4m81.2m75.8m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(11.3m)(12.7m)(26.5m)

Depreciation and Amortization

184.0k189.0k308.0k

Inventories

(8.0k)123.0k

Accounts Payable

633.0k2.0m(101.0k)
Quarterly
USDQ2, 2014Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(4.0m)(5.2m)(8.3m)(7.0m)(14.3m)(20.1m)(4.7m)(13.4m)(22.4m)

Depreciation and Amortization

72.3k90.0k137.0k73.0k148.0k227.0k69.0k138.0k206.0k

Inventories

163.5k(357.0k)(185.0k)

Accounts Payable

233.0k307.0k118.0k(398.0k)(598.0k)(146.0k)(445.0k)287.0k
USDY, 2018

EV/EBIT

-6.7 x

EV/CFO

-3.3 x

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

miRagen Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

miRagen Therapeutics News and Updates

miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman

BOULDER, Colo., Dec. 05, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the appointment of Jeff Hatfield, a Director since 2017, as Chairman of the Bo…

miRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides

BOULDER, Colo., Dec. 02, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced data from its Phase 1 clinical trial evaluating the safety, tolerability, phar…

miRagen Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update

BOULDER, Colo., Nov. 07, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today reported third quarter 2018 financial results and provided a corporate update.

miRagen Therapeutics to Present at two Investor Conferences in November 2018

BOULDER, Colo., Oct. 29, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, is sch…

miRagen Therapeutics to Report Third Quarter 2018 Financial Results and Host Conference Call on November 7, 2018

BOULDER, Colo., Oct. 24, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, November 7, 2018, at 4:30 p.m. ET to discuss its fin…
Report incorrect company information

miRagen Therapeutics Company Life and Culture

Report incorrect company information

miRagen Therapeutics Frequently Asked Questions

  • When was miRagen Therapeutics founded?

    miRagen Therapeutics was founded in 2007.

  • Who are miRagen Therapeutics key executives?

    miRagen Therapeutics's key executives are William S. Marshall and Paul Rubin.

  • How many employees does miRagen Therapeutics have?

    miRagen Therapeutics has 51 employees.

  • What is miRagen Therapeutics revenue?

    Latest miRagen Therapeutics annual revenue is $4 m.

  • What is miRagen Therapeutics revenue per employee?

    Latest miRagen Therapeutics revenue per employee is $78.5 k.

  • Who are miRagen Therapeutics competitors?

    Competitors of miRagen Therapeutics include Kewaunee, Wuxi Vision Pro and Reflexion Medical.

  • Where is miRagen Therapeutics headquarters?

    miRagen Therapeutics headquarters is located at 6200 Lookout Rd., Boulder.

  • Where are miRagen Therapeutics offices?

    miRagen Therapeutics has an office in Boulder.

  • How many offices does miRagen Therapeutics have?

    miRagen Therapeutics has 1 office.